Kurtuluş AKSU

COVID-19: Normalleşme sürecinde alerji kliniği

PDF

___

1. Lewis D. Is the coronavirus airborne? Experts can’t agree. Nature 2020;580(7802):175.
2. Somsen GA, van Rijn C, Kooij S, Bem RA, Bonn D. Small droplet aerosols in poorly ventilated spaces and SARSCoV-2 transmission [published online ahead of print, 2020 May 27]. Lancet Respir Med 2020;8(7):658-659.
3. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China [published correction appears in Lancet. 2020 Jan 30;:]. Lancet 2020;395(10223):497-506.
4. Naziroğlu T, Sözen S, Özkan P, Şeker S, Aksu K. A case of COVID-19 pneumonia presenting with acute urticaria [published online ahead of print, 2020 May 13]. Dermatol Ther 2020;e13575. doi:10.1111/dth.13575.
5. Halpin DMG, Faner R, Sibila O, Badia JR, Agusti A. Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection?. Lancet Respir Med 2020;8(5):436-438.
6. Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. Vital surveillances: the epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19)—China, 2020. China CDC Weekly. http://weekly.chinacdc.cn/en/article/ doi/10.46234/ccdcw2020.032. Erişim tarihi: 17.05.2020.
7. Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China [published online ahead of print, 2020 Feb 19]. Allergy 2020;10.1111/all.14238.
8. Li X, Xu S, Yu M, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol 2020;146(1):110-118.
9. Jackson DJ, Busse WW, Bacharier LB, et al. Association of respiratory allergy, asthma, and expression of the SARSCoV-2 receptor ACE2. J Allergy Clin Immunol 2020;146(1):203-206.e3.
10. Asthma and Allergy Foundation of America- www.aafa.org (Erişim tarihi: 16.05.2020).
11. Halpin DMG, Singh D, Hadfield RM. Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective. Eur Respir J. 2020;55(5):2001009. Published 2020 May 7. doi:10.1183/13993003.01009-2020.
12. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 2020;395(10223):473-475.
13. Yamaya M, Nishimura H, Deng X, et al. Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells. Respir Investig 2020;58(3):155-168.
14. Matsuyama S, Kawase M, Nao N, Shirato K, Ujike M, Kamitani W, Shimojima M, Fukushi S. The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15. bioRxiv 2020.03.11.987016; doi: https://doi.org/10.1101/2020.03.11.987016.
15. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2020. Available from: www.ginasthma.org (Erişim tarihi 29.06.2020).
16. https://www.medscape.com/viewarticle/927264#vp_2 (Erişim tarihi: 17.05.2020).
17. Shaker MS, Oppenheimer J, Grayson M, et al. COVID-19: Pandemic Contingency Planning for the Allergy and Immunology Clinic. J Allergy Clin Immunol Pract 2020;8(5):1477-1488.e5.
18. https://asthma.ca/get-help/asthma-3/treatment/biologics/ (Erişim tarihi: 11.07.2020).
19. Lommatzsch M, Stoll P, Virchow JC. COVID-19 in a patient with severe asthma treated with Omalizumab [published online ahead of print, 2020 Jun 16]. Allergy 2020;10.1111/ all.14456.
20. Förster-Ruhrmann U, Szczepek AJ, Bachert C, Olze H. COVID-19 in a patient with severe chronic rhinosinusitis with nasal polyps during therapy with dupilumab. J Allergy Clin Immunol 2020;146(1):218-220.e2.